These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21036774)

  • 1. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation.
    Gresele P; Falcinelli E; Loffredo F; Cimmino G; Corazzi T; Forte L; Guglielmini G; Momi S; Golino P
    Eur Heart J; 2011 Feb; 32(3):316-25. PubMed ID: 21036774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Release of MMP-2 in the circulation of patients with acute coronary syndromes undergoing percutaneous coronary intervention: Role of platelets.
    Falcinelli E; De Paolis M; Boschetti E; Gresele P
    Thromb Res; 2022 Aug; 216():84-89. PubMed ID: 35759818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
    Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
    Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome.
    Liu DM; Yan JC; Wang CP; Chen GH; Ding S; Liu PJ; Du RZ
    Clin Chim Acta; 2008 Nov; 397(1-2):22-6. PubMed ID: 18674525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
    Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
    Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates.
    Brambilla M; Camera M; Colnago D; Marenzi G; De Metrio M; Giesen PL; Balduini A; Veglia F; Gertow K; Biglioli P; Tremoli E
    Arterioscler Thromb Vasc Biol; 2008 May; 28(5):947-53. PubMed ID: 18292391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
    Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
    Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
    Fiotti N; Altamura N; Orlando C; Simi L; Reimers B; Pascotto P; Zingone B; Pascotto A; Serio M; Guarnieri G; Giansante C
    Int J Cardiol; 2008 Jul; 127(3):350-7. PubMed ID: 17706812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome.
    Yan JC; Wu ZG; Kong XT; Zong RQ; Zhan LZ
    Acta Pharmacol Sin; 2004 Feb; 25(2):251-6. PubMed ID: 14769218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin.
    Falcinelli E; Giannini S; Boschetti E; Gresele P
    Br J Haematol; 2007 Jul; 138(2):221-30. PubMed ID: 17593030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein induces expression of matrix metalloproteinase-9: a possible link between inflammation and plaque rupture.
    Cimmino G; Ragni M; Cirillo P; Petrillo G; Loffredo F; Chiariello M; Gresele P; Falcinelli E; Golino P
    Int J Cardiol; 2013 Sep; 168(2):981-6. PubMed ID: 23157807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand.
    Menchén L; Marín-Jiménez I; Arias-Salgado EG; Fontela T; Hernández-Sampelayo P; Rodríguez MC; Butta NV
    Gut; 2009 Jul; 58(7):920-8. PubMed ID: 19039088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
    Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
    Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients.
    Fernández Bello I; Álvarez MT; López-Longo FJ; Arias-Salgado EG; Martín M; Jiménez-Yuste V; Rodríguez de la Rúa A; Butta NV
    Thromb Haemost; 2012 Jan; 107(1):88-98. PubMed ID: 22116092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction.
    Ohashi Y; Kawashima S; Mori T; Terashima M; Ichikawa S; Ejiri J; Awano K
    Int J Cardiol; 2006 Sep; 112(1):52-8. PubMed ID: 16376442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of matrix metalloproteinases-1 and -2, but not -9, from activated platelets measured by enzyme-linked immunosorbent assay.
    Kälvegren H; Jönsson S; Jonasson L
    Platelets; 2011; 22(8):572-8. PubMed ID: 21756063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS).
    Bigalke B; Stellos K; Weig HJ; Geisler T; Seizer P; Kremmer E; Pötz O; Joos T; May AE; Lindemann S; Gawaz M
    Basic Res Cardiol; 2009 May; 104(3):352-7. PubMed ID: 19190951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
    Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.